Explanatory Note.
This Amendment No. 4 (this “Amendment No. 4”) amends and supplements the Schedule 13D originally filed by the Reporting Persons with the Commission on August 20, 2021, as amended and supplemented on March 30, 2022, April 26, 2022, and June 24, 2022 (as amended, the “Original Schedule 13D”). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 4 have the meanings ascribed to them in the Original Schedule 13D.
Item 1. Security and Issuer.
Item 1 of the Original Schedule 13D is hereby amended and restated in its entirety as set forth below:
“This joint statement on Schedule 13D (this “Statement”) is filed with respect to the common stock, par value $0.0001 per share (“Common Stock”), of Invivyd, Inc. (previously known as Adagio Therapeutics, Inc.), a Delaware corporation (the “Issuer”). The address of the principal executive offices of the Issuer is 1601 Trapelo Road, Suite 178, Waltham, MA 02451.”
Item 2. Identity and Background.
Item 2(b) of the Original Schedule 13D is hereby amended and restated in its entirety as set forth below:
“(b) The address of the principal offices of each Reporting Entity and the business address of each Reporting Individual is One Marina Park Drive, 8th Floor, Boston, MA 02210.”
Item 5. Interest in Securities of the Issuer.
Item 5 of the Original Schedule 13D is hereby supplemented and amended, as follows:
(a) and (b) See Items 7-11 and 13 of the cover pages of this Amendment No. 4.
(c) On December 9, 2024, Polaris IX sold 150,000 shares of Common Stock at a weighted average price per share of $0.6104 for aggregate proceeds of approximately $91,560.00.
On December 10, 2024, Polaris IX sold 175,000 shares of Common Stock at a weighted average price per share of $0.5886 for aggregate proceeds of approximately $103,005.00.
On December 11, 2024, Polaris IX sold 160,400 shares of Common Stock at a weighted average price per share of $0.5911 for aggregate proceeds of approximately $94,812.44.